research Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
Search
for
Sort by
Research
330-360 / 1000+ results
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research An Injectable Ibuprofen Sustained-Release Composite Hydrogel System Effectively Accelerates Diabetic Wound Healing via Anti-Inflammatory Effects and Angiogenesis
An injectable ibuprofen gel speeds up diabetic wound healing by reducing inflammation and promoting tissue growth.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes
Blocking a specific enzyme might help treat obesity and diabetes, but more research is needed to ensure it's safe.
research Stem of Musa Paradisiacal (Linn.) Shows the Inhibitory Effect towards Alpha Amylase and Alpha-Glucosidase Enzymes: Antidiabetic Activity
Banana stem extract may help manage diabetes by inhibiting certain enzymes.
research Eficacia y Seguridad de Metformina sobre el patrón clínico y metabólico en el Síndrome de Ovario Poliquístico: Revisión Sistemática y Metaanálisis
Metformin helps improve symptoms and reduce health risks in PCOS patients.
research Factorial Design-Based Development and Evaluation of Metformin Hydrochloride-Loaded Mucoadhesive Microspheres for Sustained Anti Hyperglycaemic and Anticancer Activity
The developed microspheres effectively deliver Metformin for sustained blood sugar control and anticancer effects.
research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
research Icariside II inhibits gastric cancer progression by suppressing the Wnt/β-catenin signaling pathway
Icariside II may help treat gastric cancer by stopping tumor growth.
research 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis
Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Syndromes of Severe Insulin Resistance (SSIRs)
The document concludes that Syndromes of Severe Insulin Resistance are rare disorders with limited treatment options.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research Upadacitinib for Alopecia: Current Evidence and Clinical Insights
Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway
Tideglusib helps heal wounds in older skin.
research Finasteride/spironolactone
research Three Cases of Alopecia Following Clinical Islet Transplantation
Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.
research Balint’s syndrome—missed or mistaken?
The document concludes that early diagnosis of Balint's syndrome is crucial for effective treatment and that understanding drug interactions, like between ritonavir and statins, is important for patient care.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research A meta-analysis of the effectiveness and safety of Sintilimab combined with chemotherapy in the trea tment of advanced non-small cell lung cancer
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
research Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport
Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
research Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.